Spectral Medical Inc T.EDT

Actually the "revised # was 605 patients","but we chose 650"

[SouthernTierTom]

* Close David...CEPT "MODS" was a "hinderance".."SOFA" is where it is at and where I can often be found after a long day of "ploughing the fields"

Questions?  Go ahead ask...that would include you too Finnoy Island buoy....you appeared near clueless when addressing the rainmark crew...not too sure if it was an act or knot...suspect sum of it was..How in the world can you folks not know the pricing on the "Mach 3" blades..AKA Dialco consumables?



David Dean, [phone] [e-mail] MORNING MEETING NOTES NOVEMBER 6, 2014 Our disclosure statements are located on the second last page of this report EUPHRATES optimally; this is a difficult and complicated group of patients to treat, and trial after trial has failed. Based upon conversations with some of the most influential physicians on the topic, we believe that the MODS modification is insightful and selects the patients who are most likely to benefit. Therefore, our confidence that EUPHRATES will report positive data is increased. Our questions are: 1) will it be too late to help these patients (i.e. has endotoxin already done its damage), and 2) will the patients die of something else? We will not know the answers to these until EUPHRATES reports, but in the meantime we believe that Spectral is on track to report a successful trial. Recall, the interim analysis showed that the trial was on track to be successful at 605 patients, suggesting an 11% or 12% absolute benefit (10% at 720 patients, 15% at 360, so the benefit within the less sick patients would be within that range and closer to the lower end). We believe that the benefit within the sicker patients will be larger than what PMX provided to the patients who were previously enrolled, so in our opinion EUPHRATES has a good shot at success. We maintain our Buy (S) rating and $1.70 target price. I, David Dean, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject company(ies) and its (their) securities. I also certify that I have not been, and will not be receiving direct or indirect compensation in exchange for expressing the specific recommendation(s) in this report

[SouthernTierTom]

Interesting this gentleman's ( former analyst attached to EDT's financing partner ) posing of question 1) ...in many ways it was "too late".  We've known for 20+ years that > .6 as an EAA ( FDA approved 2003 ) reading represented a HIGH endotoxin level.  The phase 3 Euphrates patients had a median EAA level very close to .8.  We've since learned after